PCRX
Pacira BioSciences, Inc.
$25.50
-0.02
(-0.08%)
Mkt Cap
1.00B
Volume
598,771
52W Range
18.8-27.64
Sector
Healthcare
Beta
0.27
EPS (TTM)
0.12
P/E Ratio
208.85
Revenue (TTM)
734.86M
Rev Growth (5Y)
+11.1%
EPS Growth (5Y)
-45.8%
AlphaVal · Fair Value
What we estimate one share is worth
$37.80
Undervalued
moderate signal
32.5% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
C-
Platform & Compounding FCF
44.8 / 100 composite
A platform business that compounds free cash flow — graded A–F vs. similar companies.
Company Description
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 726.41M | 700.97M | 674.98M | 666.82M | 541.53M | 429.65M | 421.03M | 337.28M | 286.63M | 276.37M | 249.00M | 197.67M |
| Net Income | 7.03M | (99.56M) | 41.95M | 15.91M | 41.98M | 145.52M | (11.02M) | (471,000) | (42.61M) | (37.95M) | 1.86M | (13.72M) |
| EPS | 0.16 | -2.15 | 0.91 | 0.35 | 0.95 | 3.41 | -0.27 | -0.01 | -1.07 | -1.02 | 0.05 | -0.39 |
| Free Cash Flow | 136.66M | 178.75M | 139.49M | 115.20M | 79.85M | 39.23M | 60.36M | 34.36M | (1.48M) | 8.74M | (12.27M) | 3.58M |
| FCF / Share | 3.07 | 3.87 | 3.02 | 2.53 | 1.80 | 0.92 | 1.45 | 0.84 | -0.04 | 0.24 | -0.34 | 0.10 |
| Operating CF | 151.99M | 189.39M | 154.65M | 145.27M | 125.72M | 77.03M | 70.52M | 48.87M | 17.79M | 33.45M | 29.00M | 25.47M |
| Total Assets | 1.26B | 1.55B | 1.57B | 1.68B | 2.08B | 1.27B | 831.07M | 689.35M | 628.37M | 391.47M | 389.62M | 326.07M |
| Total Debt | 454.38M | 638.85M | 586.04M | 763.39M | 1.13B | 541.13M | 351.92M | 290.93M | 276.50M | 108.74M | 105.93M | 103.10M |
| Cash & Equiv | 158.54M | 276.77M | 153.30M | 104.14M | 585.58M | 99.96M | 78.23M | 132.53M | 54.13M | 35.94M | 158.97M | 158.17M |
| Book Value | 693.11M | 778.35M | 870.13M | 775.01M | 730.41M | 619.69M | 354.94M | 321.23M | 279.48M | 218.98M | 218.39M | 171.15M |
| Return on Equity | 0.01 | -0.13 | 0.05 | 0.02 | 0.06 | 0.23 | -0.03 | -0.00 | -0.15 | -0.17 | 0.01 | -0.08 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 177.38M | 196.87M | 179.52M | 181.10M | 168.92M | 187.25M | 168.57M | 178.02M | 167.12M | 181.24M | 163.93M | 169.47M |
| Net Income | 2.92M | 1.64M | 5.43M | (4.85M) | 4.81M | 16.04M | (143.47M) | 18.89M | 8.98M | 24.87M | 10.86M | 25.76M |
| EPS | 0.07 | 0.04 | 0.12 | -0.11 | 0.10 | 0.35 | -3.11 | 0.41 | 0.19 | 0.54 | 0.23 | 0.56 |
| Free Cash Flow | 22.96M | 43.47M | 56.96M | 9.31M | 26.91M | 31.01M | 49.83M | 51.65M | 46.27M | 45.79M | 41.04M | 40.09M |
| FCF / Share | 0.57 | 1.02 | 1.29 | 0.20 | 0.58 | 0.67 | 1.08 | 1.12 | 0.99 | 0.99 | 0.88 | 0.87 |
| Operating CF | 25.68M | 43.69M | 60.83M | 12.01M | 35.46M | 33.13M | 53.92M | 53.24M | 49.10M | 47.58M | 44.44M | 43.50M |
| Total Assets | 1.21B | 1.26B | 1.30B | 1.54B | 1.59B | 1.55B | 1.52B | 1.65B | 1.58B | 1.57B | 1.53B | 1.54B |
| Total Debt | 411.18M | 454.38M | 425.31M | 631.40M | 636.46M | 638.85M | 644.42M | 648.60M | 581.78M | 586.04M | 590.30M | 620.71M |
| Cash & Equiv | 144.31M | 158.54M | 147.59M | 300.48M | 283.61M | 276.77M | 245.97M | 247.05M | 184.05M | 153.30M | 99.12M | 86.81M |
| Book Value | 653.89M | 693.11M | 727.21M | 757.77M | 798.54M | 778.35M | 749.58M | 879.28M | 892.16M | 870.13M | 831.55M | 807.98M |
| Return on Equity | 0.00 | 0.00 | 0.01 | -0.01 | 0.01 | 0.02 | -0.19 | 0.02 | 0.01 | 0.03 | 0.01 | 0.03 |
PCRX News
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Deal
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®
Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet
Pacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual Meeting
Pacira BioSciences, Inc. (PCRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Pacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual Meeting
Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees
PharmaCorp Rx Inc. Announces First Quarter 2026 Financial Results
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira's Director Nominees